Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Restructuring expense: $181M in Q3 2026, up 187.3% from a year earlier.
Latest, Q3 2026
181
Period ended Sep 30, 2026
Change on a year earlier
+187.3%
63 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
31
Documents cited below
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-21) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Restructuring Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson Restructuring expense ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/restructuring-exp
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.